Genetic control of HIV disease

Trends in Microbiology

Volumn 11, Issue 8, 2003, Pages 392-397

  Theodorou, Ioannis ^a   Capoulade, Corinne ^a   Combadiere, Christophe ^a   Debre, Patrice ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DISEASE COURSE; DNA POLYMORPHISM; DRUG METABOLISM; GENE FUNCTION; GENETIC REGULATION; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION RESISTANCE; INFECTION SENSITIVITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SURVIVAL; TREATMENT OUTCOME; VIRAL GENETICS; GENETIC PREDISPOSITION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; PATHOGENICITY; PATHOPHYSIOLOGY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HIV; HIV INFECTIONS; HUMANS; VARIATION (GENETICS);

EID: 0141907316     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-842X(03)00177-X     Document Type: Review

References (58)

1. Abel L., Dessein A.J. The impact of host genetics on susceptibility to human infectious diseases. Curr. Opin. Immunol. 9:1997;509-516.
2. Deacon N.J., et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science. 270:1995;988-991.
3. Marquet S., et al. Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Nat. Genet. 14:1996;181-184.
4. Murphy P.M. Chemokine receptors: structure, function and role in microbial pathogenesis. Cytokine Growth Factor Rev. 7:1996;47-64.
5. Pareja E., et al. The tetramer model: a new view of class II MHC molecules in antigenic presentation to T cells. Tissue Antigens. 50:1997;421-428.
6. Williams A., et al. The cell biology of MHC class I antigen presentation. Tissue Antigens. 59:2002;3-17.
7. Alkhatib G., et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1996;1955-1958.
8. Dragic T., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:1996;667-673.
9. Deng H., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:1996;661-666.
10. Stephens J.C., et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am. J. Hum. Genet. 62:1998;1507-1515.
11. Samson M., et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382:1996;722-725.
12. Theodorou I., et al. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet. 349:1997;1219-1220.
13. Dean M., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia growth and development study, multicenter aids cohort study, multicenter hemophilia cohort study, San Francisco City Cohort, ALIVE Study. Science. 273:1996;1856-1862.
14. Meyer L., et al. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. AIDS. 11:1997;F73-F78.
15. Contopoulos-Ioannidis D.G., et al. Effect of CCR5-delta32 heterozygosity on the risk of perinatal HIV-1 infection: a meta-analysis. J. Acquir. Immune Defic. Syndr. 32:2003;70-76.
16. Kaul R., et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 164:2000;1602-1611.
17. MacDonald K.S., et al. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 181:2000;1581-1589.
18. MacDonald K.S., et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J. Infect. Dis. 177:1998;551-556.
19. Polycarpou A., et al. Association between maternal and infant class I and II HLA alleles and of their concordance with the risk of perinatal HIV type 1 transmission. AIDS Res. Hum. Retroviruses. 18:2002;741-746.
20. Zimmerman P.A., et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3:1997;23-36.
21. Ioannidis J.P., et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann. Intern. Med. 135:2001;782-795.
22. Misrahi M., et al. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French pediatric HIV infection study group. JAMA. 279:1998;277-280.
23. McDermott D.H., et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS cohort study (MACS). Lancet. 352:1998;866-870.
24. Martin M.P., et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science. 282:1998;1907-1911.
25. Lee B., et al. Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J. Virol. 72:1998;7450-7458.
26. Smith M.W., et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia growth and development study (HGDS), multicenter AIDS cohort study (MACS), multicenter hemophilia cohort study (MHCS), San Francisco City Cohort (SFCC), ALIVE study. Science. 277:1997;959-965.
27. Kostrikis L.G., et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat. Med. 4:1998;350-353.
28. Liu H., et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. U. S. A. 96:1999;4581-4585.
29. McDermott D.H., et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the multicenter AIDS cohort study. AIDS. 14:2000;2671-2678.
30. An P., et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc. Natl. Acad. Sci. U. S. A. 99:2002;10002-10007.
31. Winkler C., et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant, ALIVE study, hemophilia growth and development study (HGDS), multicenter AIDS cohort study (MACS), multicenter hemophilia cohort study (MHCS), San Francisco city cohort (SFCC). Science. 279:1998;389-393.
32. Faure S., et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science. 287:2000;2274-2277.
33. McDermott D.H., et al. Genetic polymorphism in CX3CR1 and risk of HIV disease. Science. 290:2000;2031.
34. Hill A.V. Genetic susceptibility to malaria and other infectious diseases: from the MHC to the whole genome. Parasitology. 112:(Suppl.):1996;S75- S84.
35. Moore C.B., et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science. 296:2002;1439-1443.
36. Magierowska M., et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood. 93:1999;936-941.
37. Kaslow R.A., et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2:1996;405-411.
38. Gao X., et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344:2001;1668-1675.
39. *04 disadvantage. Science. 283:1999;1748-1752.
40. Martin M.P., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31:2002;429-434.
41. Shin H.D., et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc. Natl. Acad. Sci. U. S. A. 97:2000;14467-14472.
42. Nakayama E.E., et al. Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J. Virol. 74:2000;5452-5459.
43. Nakayama E.E., et al. Protective effect of interleukin-4 -589T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load. J. Infect. Dis. 185:2002;1183-1186.
44. Turner M.W. Mannose-binding lectin (MBL) in health and disease. Immunobiology. 199:1998;327-339.
45. Garred P., et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet. 349:1997;236-240.
46. Malik S., et al. Absence of association between mannose-binding lectin gene polymorphisms and HIV-1 infection in a Colombian population. Immunogenetics. 55:2003;49-52.
47. French M.A. Antiretroviral therapy. Immune restoration disease in HIV-infected patients on HAART. AIDS Read. 9:1999;548-562.
48. Guerin S., et al. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 14:2000;2788-2790.
49. Kasten S., et al. Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients. Eur. J. Med. Res. 5:2000;323-328.
50. Wit F.W., et al. CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. J. Infect. Dis. 186:2002;1726-1732.
51. Brumme Z.L., et al. CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. AIDS. 15:2001;2259-2266.
52. Hetherington S., et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 359:2002;1121-1122.
53. *5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 359:2002;727-732.
54. Maher B., et al. TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS. 16:2002;2013-2018.
55. Danielson P.B. The cytochrome p450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 3:2002;561-597.
56. Fellay J., et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 359:2002;30-36.
57. Carson S.W., et al. Emerging significance of P-glycoprotein in understanding drug disposition and drug interactions in psychopharmacology. Psychopharmacol. Bull. 36:2002;67-81.
58. Ioannidis J.P. Genetic associations: false or true? Trends Mol. Med. 9:2003;135-138.